Flora Growth (FLGC) Competitors

$4.97 -0.22 (-4.26%)

As of 05/4/2026

FLGC vs. BTAI, BCTX, TVGN, CELU, and TVRD

Should you be buying Flora Growth stock or one of its competitors? The main competitors of Flora Growth include BioXcel Therapeutics (BTAI), Briacell Therap (BCTX), Tevogen Bio (TVGN), Celularity (CELU), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry.

How does Flora Growth compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

: BioXcel Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.
: 30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: BioXcel Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 780.00%. Flora Growth has a consensus target price of $30.00, indicating a potential upside of 503.62%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Flora Growth.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioXcel Therapeutics
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
Flora Growth
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, BioXcel Therapeutics and BioXcel Therapeutics both had 1 articles in the media. Flora Growth's average media sentiment score of 0.84 beat BioXcel Therapeutics' score of 0.50 indicating that Flora Growth is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioXcel Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Flora Growth
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Flora Growth has a net margin of -32.03% compared to BioXcel Therapeutics' net margin of -10,887.38%. BioXcel Therapeutics' return on equity of 0.00% beat Flora Growth's return on equity.
Company Net Margins Return on Equity Return on Assets
BioXcel Therapeutics -10,887.38% N/A -181.48%
Flora Growth -32.03% -64.02% -34.46%
: Flora Growth has higher revenue and earnings than BioXcel Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioXcel Therapeutics $640K 52.89 -$69.90M -$6.71 N/A
Flora Growth $57.61M 0.09 -$15.91M -$32.49 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioXcel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Flora Growth	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-10,887.38%	N/A	-181.48%
Flora Growth	-32.03%	-64.02%	-34.46%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	52.89	-$69.90M	-$6.71	N/A
Flora Growth	$57.61M	0.09	-$15.91M	-$32.49	N/A

Summary

Flora Growth beats BioXcel Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Flora Growth compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

: In the previous week, Flora Growth had 1 more articles in the media than Briacell Therap. MarketBeat recorded 1 mentions for Flora Growth and 0 mentions for Briacell Therap. Flora Growth's average media sentiment score of 0.84 beat Briacell Therap's score of 0.00 indicating that Flora Growth is being referred to more favorably in the news media.
Company Overall Sentiment
Briacell Therap Neutral
Flora Growth Positive
: 15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Comparatively, 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: Flora Growth has a consensus target price of $30.00, indicating a potential upside of 503.62%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts plainly believe Flora Growth is more favorable than Briacell Therap.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Briacell Therap
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Flora Growth
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Briacell Therap has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.
: Flora Growth has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Briacell Therap N/A N/A -$26.31M -$23.33 N/A
Flora Growth $57.61M 0.09 -$15.91M -$32.49 N/A
: Briacell Therap has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Briacell Therap's return on equity.
Company Net Margins Return on Equity Return on Assets
Briacell Therap N/A -173.08% -139.64%
Flora Growth -32.03% -64.02% -34.46%

Company	Overall Sentiment
Briacell Therap	Neutral
Flora Growth	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
Flora Growth	$57.61M	0.09	-$15.91M	-$32.49	N/A

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
Flora Growth	-32.03%	-64.02%	-34.46%

Summary

Flora Growth beats Briacell Therap on 13 of the 15 factors compared between the two stocks.

How does Flora Growth compare to Tevogen Bio?

Flora Growth (NASDAQ:FLGC) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

: In the previous week, Flora Growth and Flora Growth both had 1 articles in the media. Flora Growth's average media sentiment score of 0.84 beat Tevogen Bio's score of 0.00 indicating that Flora Growth is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Flora Growth
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tevogen Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 36.0% of Flora Growth shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by company insiders. Comparatively, 70.5% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: Flora Growth currently has a consensus target price of $30.00, indicating a potential upside of 503.62%. Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,256.85%. Given Tevogen Bio's higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Flora Growth.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flora Growth
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Tevogen Bio
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50
: Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.
: Flora Growth has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Flora Growth $57.61M 0.09 -$15.91M -$32.49 N/A
Tevogen Bio N/A N/A -$26.27M -$9.50 N/A
: Tevogen Bio has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Tevogen Bio's return on equity of 0.00% beat Flora Growth's return on equity.
Company Net Margins Return on Equity Return on Assets
Flora Growth -32.03% -64.02% -34.46%
Tevogen Bio N/A N/A -610.37%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Flora Growth	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.09	-$15.91M	-$32.49	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$9.50	N/A

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
Tevogen Bio	N/A	N/A	-610.37%

Summary

Flora Growth beats Tevogen Bio on 9 of the 14 factors compared between the two stocks.

How does Flora Growth compare to Celularity?

Flora Growth (NASDAQ:FLGC) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

: Flora Growth has a net margin of -32.03% compared to Celularity's net margin of -198.75%. Celularity's return on equity of 0.00% beat Flora Growth's return on equity.
Company Net Margins Return on Equity Return on Assets
Flora Growth -32.03% -64.02% -34.46%
Celularity -198.75% N/A -65.03%
: Flora Growth has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.
: Flora Growth presently has a consensus target price of $30.00, suggesting a potential upside of 503.62%. Celularity has a consensus target price of $6.00, suggesting a potential upside of 529.66%. Given Celularity's higher probable upside, analysts plainly believe Celularity is more favorable than Flora Growth.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flora Growth
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Celularity
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: 36.0% of Flora Growth shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 2.3% of Flora Growth shares are held by insiders. Comparatively, 17.3% of Celularity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Flora Growth has higher revenue and earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Flora Growth $57.61M 0.09 -$15.91M -$32.49 N/A
Celularity $26.55M 1.04 -$57.89M -$3.33 N/A
: In the previous week, Celularity had 1 more articles in the media than Flora Growth. MarketBeat recorded 2 mentions for Celularity and 1 mentions for Flora Growth. Flora Growth's average media sentiment score of 0.84 beat Celularity's score of 0.20 indicating that Flora Growth is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Flora Growth
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celularity
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
Celularity	-198.75%	N/A	-65.03%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.09	-$15.91M	-$32.49	N/A
Celularity	$26.55M	1.04	-$57.89M	-$3.33	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Flora Growth	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Flora Growth beats Celularity on 8 of the 14 factors compared between the two stocks.

How does Flora Growth compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

: Tvardi Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Tvardi Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Tvardi Therapeutics N/A -73.53% -35.22%
Flora Growth -32.03% -64.02% -34.46%
: Tvardi Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.
: Tvardi Therapeutics presently has a consensus target price of $55.50, suggesting a potential upside of 1,404.07%. Flora Growth has a consensus target price of $30.00, suggesting a potential upside of 503.62%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tvardi Therapeutics is more favorable than Flora Growth.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tvardi Therapeutics
1 Sell rating(s)
3 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.50
Flora Growth
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: 44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 3.1% of Tvardi Therapeutics shares are held by insiders. Comparatively, 2.3% of Flora Growth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Flora Growth has higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tvardi Therapeutics $7.14M 4.85 -$18.21M -$5.59 N/A
Flora Growth $57.61M 0.09 -$15.91M -$32.49 N/A
: In the previous week, Flora Growth had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 1 mentions for Flora Growth and 0 mentions for Tvardi Therapeutics. Flora Growth's average media sentiment score of 0.84 beat Tvardi Therapeutics' score of 0.00 indicating that Flora Growth is being referred to more favorably in the news media.
Company Overall Sentiment
Tvardi Therapeutics Neutral
Flora Growth Positive

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-73.53%	-35.22%
Flora Growth	-32.03%	-64.02%	-34.46%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	4.85	-$18.21M	-$5.59	N/A
Flora Growth	$57.61M	0.09	-$15.91M	-$32.49	N/A

Company	Overall Sentiment
Tvardi Therapeutics	Neutral
Flora Growth	Positive

Summary

Tvardi Therapeutics beats Flora Growth on 9 of the 17 factors compared between the two stocks.

Get Flora Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGC vs. The Competition

Export

Metric	Flora Growth	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.20M	$8.27B	$6.25B	$11.77B
Dividend Yield	N/A	2.48%	2.74%	5.26%
P/E Ratio	-0.15	101.05	24.91	23.23
Price / Sales	0.09	8.18	504.56	75.49
Price / Cash	N/A	16.86	43.30	53.90
Price / Book	0.41	3.52	9.67	6.69
Net Income	-$15.91M	$223.69M	$3.55B	$332.64M
7 Day Performance	-29.80%	0.07%	1.70%	2.01%
1 Month Performance	-11.57%	10.31%	5.62%	9.19%
1 Year Performance	-77.01%	0.92%	34.42%	39.59%

Flora Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGC Flora Growth	1.8976 of 5 stars	$4.97 -4.3%	$30.00 +503.6%	N/A	$5.20M	$57.61M	N/A	280	Gap Up
BTAI BioXcel Therapeutics	2.2105 of 5 stars	$1.06 -2.8%	$11.00 +937.7%	N/A	$29.51M	$640K	N/A	90	Upcoming Earnings
BCTX Briacell Therap	0.6126 of 5 stars	$4.06 +0.7%	N/A	N/A	$29.22M	N/A	N/A	8
TVGN Tevogen Bio	1.2051 of 5 stars	$6.49 -7.3%	$100.00 +1,440.8%	N/A	$29.15M	N/A	N/A	3	News Coverage
CELU Celularity	1.6093 of 5 stars	$1.04 +5.1%	$6.00 +476.9%	N/A	$28.55M	$54.22M	N/A	220	Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGC) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Flora Growth (FLGC) Competitors

FLGC vs. BTAI, BCTX, TVGN, CELU, and TVRD

How does Flora Growth compare to BioXcel Therapeutics?

Summary

How does Flora Growth compare to Briacell Therap?

Summary

How does Flora Growth compare to Tevogen Bio?

Summary

How does Flora Growth compare to Celularity?

Summary

How does Flora Growth compare to Tvardi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC vs. The Competition

Flora Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Flora Growth (FLGC) Competitors

FLGC vs. BTAI, BCTX, TVGN, CELU, and TVRD

How does Flora Growth compare to BioXcel Therapeutics?

Summary

How does Flora Growth compare to Briacell Therap?

Summary

How does Flora Growth compare to Tevogen Bio?

Summary

How does Flora Growth compare to Celularity?

Summary

How does Flora Growth compare to Tvardi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC vs. The Competition

Flora Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools